BETNOVATE OINT; betamethsone, dermatological agents .
ACTIVE-INGREDIENT OF BETNOVATE OINT
IT CONTAIN 0.122 % w/w betamethasone 17-valerate 0.122% w/w .
INDICATION OF BETNOVATE OINT
BETNOVATE is a potent topical corticosteriod indicated for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses . these include the following :- atopic dermatitis . – nummular dermatitis ( discoid eczema ) – prurigo nodularis .- psoriasis( excluding widespread plaque psoriasis ) .- lichen simplex chronicus ( neurodermatitis) and lichen planus .- seborrhoeic dermatits – initial or allergic contact dermatitis – discoid lupus erythematosus – adjunct to systematic steroid therapy in generalised erythroderma . – insect bite reactions .- miliaria (pickly heat ) .-
DOSAGE OF BETNOVATE OINT
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
adults,elderly and children over 1 year , OINTMENT is especially appropriate for dry ,lichenified or scaly lesions . Adults and adolescents : apply a thinly and gently rub in using enough to cover the entire affected area once or twice daily for up to 4 weeks , until improvement occurs , then reduce the frequency of application or change the treatment to a less potent preparation . allow adequate time for absorbtion after each application before applying an emolient . in the more resistant lesions , such as the thickened plaques of psoriasis on elbows and knees , the effect of betnovate can be enhanced , if necessary , by occluding the treatment area with polythene film . overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions , thereafter improvement can usually be maintained by regular application without occlusion . if the condition worsens or does not improve withen 2-4 weeks treatment and diagnosis should be re-evaluated . children : betnovate is contraindicated in children under one year of age. children are more likely to develop local and systemic side effects of topical corticosteroids and, in general , requir shorter courses and less pontent agents than adults care should be taken when using betnovate to ensure the amount applied is the minimum that provides therapeutic benefit , – elderly : clinical studies have not identified differences in responses between the elderlty and younger patients . the greater frequency of decreased hepatic or renal function in the elderly may delay elimintation if systematic absorption occurs . therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical beni=efit . – renal / hepatic impairment : in case of systematic absorption ( when application is over a large surface area for a prolonged period ) metabolism and elimintation may be delyed therfore increasing the risk of systematic toxictly . therefore the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit .
OVER-DOSAGE OF BETNOVATE OINT
symptoms and signs : topically applied betamethasone valerate may be absorped in sufficient amounts to produce systemic effects , acute overdosage is very unlikely to occur , however , in the case of chronicoverdosage or misuse the features of hypercortisolism may occur .
CONTRA-INDICATION OF BETNOVATE OINT
the following conditions should not be treated with BETNOVATE : – untreated cutaneous infections .rosacea – acne vulgaris – perioral dermatitis – pruritus without inflammation -perianal and genital pruritus – perioral dermatitis . BETNOVATE N is contraindicated in dermatoses in infants under one year of age , including dermatitis .
STORAGE OF BETNOVATE OINT
store at temperature not exceeding 30 ° C .
PACK OF BETNOVATE OINT
BETNOVATE ointment is provide in alluminium tubes each of 15 gm
BETNOVATE OINT MANUFACTURED BY
Smithkline Beecham – El -Giza-EGYPT For : Glaxosmithkline Egypt.